FOXO4-DRI Reference
Educational, not medical advice reference for FOXO4-DRI: Longevity, Recovery; regulatory status, evidence posture, source review, and schedule n…
Plain English
- What it is
- FOXO4-DRI is a lab-made peptide used only in research. It is not an approved medicine and has no FDA label. Scientists study it as a 'senolytic,' which means something meant to clear out old, worn-out cells that have stopped dividing but will not die.
- What people use it for
- In the longevity crowd, people chase it hoping to slow aging, boost fertility, and help tissue repair. Those hopes come from cell and animal studies, not from proven results in people.
- What the science shows
- In mice and in lab dishes, it can target and remove these aging cells by blocking a protein interaction inside them, and related mouse work links it to better sperm quality and less lung scarring. Human results for safety and benefit are missing, so the real effects in people are unknown.
- The catch
- Almost all of the evidence is from animals and cells, with no human trials, so anti-aging, fertility, and other claims are unproven. Clearing out aging cells is not automatically safe, and this is an unapproved research chemical whose risks have not been worked out in people.
Reference summary
Mouse and cell-model studies report FOXO4-p53 disruption and senescent-cell targeting. Human efficacy and safety data are absent.
Regulatory and posture
- Categories
- Longevity, Recovery
- Aliases
- FOXO4-D-Retro-Inverso, FOXO4-p53 interfering peptide, Senolytic peptide
- Evidence posture
- preclinical - Preclinical senolytic. Anti-aging and fertility claims are animal / cell-model extrapolations. Removing senescent cells may carry biology-specific risks that have not been resolved in humans.
- Regulatory status
- No FDA-approved FOXO4-DRI drug label. Published work is preclinical and mechanistic; there is no approved senolytic peptide product for anti-aging, fertility, fibrosis, or cancer-adjunct use.
- Content review status
- research reference
Selected public sources
- FDA bulk drug substances with significant safety risks
- PubMed: FOXO4-DRI targeted apoptosis of senescent cells
- PubMed: FOXO4-DRI pulmonary-fibrosis mouse study
- PubMed: FOXO4-DRI aged-mouse spermatogenesis study
Related tools
- Injection-site rotation overview - Public overview of the Pro site-rotation planner.
- Protocol builder overview - Public overview of the Pro protocol builder.
For research and educational purposes only. Not medical advice.